E.B. PEREDERYAEVA, T.B. PSHENICHNIKOVA, A.D. MAKATSARIYA 

I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., Moscow, Russian Fedration, 119991

Perederyaeva E.B. — Candidate of Medical Science, Junior research scientist of scientific and research division «Maternity and child welfare service» of Scientific and Research Center, tel. +7-903-1444073, e-mail: katya-oleg@yandex.ru¹

Pshenichnikova T.B. — Candidate of Medical Science, Junior research scientist of scientific and research division «Maternity and child welfare service» of Scientific and Research Center, tel. +7-903-144-40-72, e-mail: tanya-katya@yandex.ru¹

Makatsariya A.D. — Corresponding member of RAMS, D. med. Sc., Professor, Head of the Department of Obstetrics and Gynecology of Public Health Faculty, tel. +7-903-728-08-97, e-mail: gemostasis@mail.ru¹

Metabolic syndrome is widespread among women of reproductive age. Metabolic syndrome is the risk factor for developing various obstetric complications. Genetic hypofibrinolysis in women with metabolic syndrome in conjunction with other forms of thrombophilia cause abnormalities of implantation, trophoblast invasion, placentation. It may cause gestosis progression, pheto-placental insufficiency, syndrome of intra-uterine growth retardation of a fetus, syndrome of a fetus loss at the time of pregnancy.

Key words: metabolic syndrome, thrombophilia, pregnancy.

 

 

REFERENCES

1. Makolkin V.I. Metabolicheskiy sindrom [Metabolic syndrome]. Moscow, Medical Information Agency Publ., 2010. 144 p.

2. Makatsariya A.D., Pshenichnikova E.B., Pshenichnikova T.B., Bitsadze V.O. Metabolicheskiy sindrom i trombofiliya v akusherstve i ginekologii [Metabolic syndrome and thrombophilia in obstetrics and gynecology]. Moscow, Medical Information Agency Publ., 2006. 480 p.

3. Mychka V.B., Chazova I.E. Metabolic syndrome: Diagnosis and differentiated approach to treatment. Kachestvozhizni. Meditsina, 2005, no. 3, pp. 28-33. (in Russ.).

4. Botella Llusia J. Metabolic syndrome X in women. Anales de la Real Academia Nacional de Medicina, 2000, vol. 117, no. 2, pp. 317-327. (in Spanish).

5. Avogaro P., Crepaldi G., Enzi G., Tiengo A. Metabolic aspects of essential obesity. Epatologia Roma, 1965, vol. 11, no. 3, pp. 226-238. (in Italian).

6. Mehnert H., Kuhlmann H. Hypertonie and diabetes mellitus. Deutsches medizinisches Journal, 1968. vol. 19, no. 16, pp. 567-571. (in German).

7. Reaven G.M. Role of insulin resistance in human disease. Diabetes, 1988, vol. 37, no. 12, pp. 1595-1607.

8. Kaplan N.M. The deadly quartet: Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Archives of Internal Medicine, 1989, vol. 149, no. 7, pp. 1514-1520.

9. Bjorntorp P. Coronary disease and obesity. Medicographia, 1991, vol. 13, no. 1, pp. 45-47.

10. DeFronzo R., Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dislipidemia and atherosclerotic cardio-vascular disease. Diabetes Care, 1991, vol. 4, no. 3, pp. 173-194.

11. Resnick L.M. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of “syndrome X”. American Journal of Hypertension, 1993, vol. 6, no. 4, pp. 123s-134s.

12. Enzi G., Busetto L., Carraro R. Association of multiple risk factors for cardiovascular disease and visceral obesity. A deadly quartet or sextet? ObesityinEurope. London, JohnLibbeyPubl. 1994, pp. 411-418.

13. Volkova E.G., Kalev O.F. Rukovodstvo po korrektsii lipidnykh narusheniy i ateroskleroza u bol’nykh sakharnym diabetom [Manual for correction of lipid disorders and atherosclerosis in patients with diabetes]. Chelyabinsk, 1995. 63 p.

14. Zimin Yu.V. Metabolic disorders within the metabolic syndrome X (insulin resistance syndrome): The need for strict application of diagnostic criteria for the syndrome. Kardiologiya, 1999, no. 8, pp. 59-67. (in Russ.).

15. Henefeld M., LeonhardtW. The metabolicsyndrome. Deutsche Gesundheitswesen, 1980, no. 36, pp. 545-551. (in German).

16. Belotserkovtseva L.D., Kovalenko L.V., Korneeva E.V., Mayer Yu.I., Shishanok O.Yu., Erchenko E.N. Osobennosti metabolicheskogo sindroma u zhenshchin v razlichnye periody zhizni: patogenez, klinika, diagnostika, lechenie [Features of the metabolic syndrome in women in different stages of life: Pathogenesis, clinical manifestations, diagnosis, treatment]. Moscow, Academy of Natural Sciences Publ., 2010. 73 p.

17. Borovkova E.I. Prenatal care for patients with overweight and obesity. Mat. obrazov. semin. “Reproduktivnoe zdorov’e zhenshchin vne i vo vremya beremennosti” [Mat. educ. semin. “Women’sreproductivehealthoutof, andduringpregnancy”]. Moscow, 2010. pp. 23-27.

18. Barker D.J. Maternal nutrition, fetal nutrition, and disease in later life. Nutrition, 1997, vol. 13, no. 19, pp. 807-813.

19. Kuzin A.I., Lengin Yu.A. Metabolicheskiy sindrom: klinicheskie i populyatsionnye aspekty [Metabolic syndrome: clinical and population aspects]. Chelyabinsk, 2001. 90 p.

20. Dmitriev A.N. Ozhirenie i metabolicheskiy sindrom [Obesityand metabolic syndrome]. Ekaterinburg, Ural State Medical Academy Publ., 2001. 160 p.

21. Mamedov M.N. Komponenty metabolicheskogo sindroma u bol’nykh s arterial’noy gipertoniey. Kand. med. nauk diss. Avtoref. [Components of the metabolic syndrome in patients with hypertension. Cand. med. sci. diss. Synopsis]. Moscow, 1997.

22. Belyakov N.A., Mazurov V.I., eds. Ozhirenie. Rukovodstvo dlya vrachey [Obesity. Guideforphysicians]. St. Petersburg, SPb MAPO Publ., 2003, pp. 96-119.

23. Dedov I.I., Mel’nichenko G.A. Ozhirenie. Etiologiya, patogenez, klinicheskie aspekty [Obesity. Etiology, pathogenesis,clinical aspects]. Moscow, Medical Information Agency Publ., 2004, pp. 216-232.

24. Eckel R.H. Obesity: Mechanisms and clinical management. Philadelphia, Lippincott Williams & Wilkins Publ., 2003, pp. 378-398.

25. Wannamethee S.G., Lowe G.D.O., Shaper A.G., Rumley A., Lennon L., Whincup P.H. Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease. Diabetologia, 2004, vol. 47, no. 9, pp. 1557-1565. DOI: 10.1007/s00125-004-1491-7.

26. Semikhnenko I.N. Klinicheskoe znachenie vitaminnogo disbalansa u bol’nykh s metabolicheskim sindromom. Kand. med. nauk diss. Avtoref. [Clinical significance of vitamin imbalance in patients with metabolic syndrome. Cand. med. sci. diss. Synopsis]. Tyumen’, 2003. 30 p.

27. Boucher B.J. Inadequate vitamin D status: Does it contribute to the disorders comprising syndrome ‘X’? British Journal of Nutrition, 1998, vol. 79, no. 4, pp. 315-327.

28. Chiu K.C., Chu A., Go V.L.W., Saad M.F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. American Journal of Clinical Nutrition, 2004, vol. 79, no. 5, pp. 820-825.

29. Takaya J., Higashino H., Kobayashi Y. Intracellular magnesium and insulin resistance. Magnesium Research, 2004, vol. 17, no. 2, pp. 126-136.

30. Guerrero-Romero F., Rodrigues-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetologica, 2002, vol. 39, no. 4, pp. 209-213. DOI:10.1007/s005920200036.

31. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NOEP) Expert Panel on detection, evaluation and Treatment of high blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: The Journal of the American Medical Association, 2001, vol. 285, no. 19, pp. 2486-2497. DOI:10.1001/jama.285.19.2486.

32. AACE position statement on insulin resistance syndrome. ACE guidelines for glycemic control. Endocrine Practice, 2003, vol. 9, Suppl. 1, pp. 7-19.

33. Aldhahi W., Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Current Diabetes Reports, 2003, vol. 3, no. 4, pp. 293-298.

34. Festa A., D’Agostino R. Jr., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes, 2002, no. 51, pp. 1131-1137.

35. Hoekstra T., Geleijnse J.M., Schouten E.G., Kok F.J., Kluft C. Relationship of C-reactive protein with components of the metabolic syndrome in normal-weight and overweight elderly. Nutrition, Metabolism and Cardiovascular Diseases, 2005, vol. 15, no. 4, pp. 270-278. DOI:10.1016/j.numecd.2005.01.004.

36. Aso Y., Wakabayashi S., Yamamoto R. et al. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care, 2005, vol. 28, no. 9, pp. 2211-2216.

37. Gadaeva Z.K. Frequency and spectrum of polymorphisms of proinflammatory cytokines and thrombophilia in women with metabolic syndrome and gestosis. Mat. X yubileyn.Vseross. nauch. foruma “Mat’ i Ditya” [Proc. 10^th Jubilee All-Russ. Sci. Forum “Mother and Child”]. Moscow, “MEDI Ekspo” Publ., 2009, p. 42.

38. Andersen P. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: Relationship to the metabolic cardiovascular syndrome. Journal of Cardiovascular Pharmacology, 1992, vol. 20, Suppl. 8, pp. S29-S31.

39. Imperatore G., Riccardi G., Iovine C., Rivellese A.A., Vaccaro O. Plasma fibrinogen: A new factor of the metabolic syndrome: A population-based study. Diabetes Care, 1998, vol. 21, no. 4, pp. 649-654. DOI:10.2337/diacare.21.4.649.

40. Skurk T., Hauner H. Obesity and impaired fibrinolysis: Role of adipose production of plasminogen activator inhibitor-1. International Journal of Obesity, 2004, vol. 28, no. 11, pp. 1357-1364. DOI: 10.1038/sj.ijo.0802778.

41. Makatsariya A.D., Bitsadze V.O. Trombofilii i protivotromboticheskaya terapiya v akusherskoy praktike [Thrombophilia and antithrombotic therapy in obstetric practice]. Moscow, Triada-X Publ., 2003. 904 p.

42. Cigolini M., Tonoli M., Borgato L.,Frigotto L., Manzato F., Zeminian S., Cardinale C., et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: A role for TNF-alpha? Atherosclerosis, 1999, vol. 143, no. 1, pp. 81-90. DOI:10.1016/S0021-9150(98)00281-0.

43. Dimova E.Y., Samoylenko A., Kietzmann T. Oxidative stress and hypoxia: Implications for plasminogen activator inhibitor-1 expression. Antioxidants and Redox Signaling, 2004, vol. 6, no. 4, pp. 777-791. DOI: 10.1089/1523086041361596.

44. Vaughan D.E. PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis, 2005, vol. 3, no. 8, pp. 1879-1883. DOI:10.1111/j.1538-7836.2005.01420.x.

45. Bitsadze V.O. Patogenez, printsipy diagnostiki i profilaktiki oslozhneniy beremennosti, obuslovlennykh trombofiliey. Dokt. med. nauk. diss. Avtoref. [Pathogenesis, principles of diagnosis and prevention of complications in pregnancy due to thrombophilia. Dr. med. sci. diss. Synopsis]. Moscow, 2004.

46. Bitsadze V.O., Makatsariya A.D., Baymuradova S.M., Akin’shina S.V. Prevention of repeated gestoses in patients with thrombophilia. Mat. XI Vseross. nauch. foruma “Mat’ i Ditya” [Proc. 11^th All-Russ. Sci. Forum “Mother and Child”]. Moscow, “MEDI Ekspo” Publ., 2010, pp. 29-30.

47. Bitsadze V.O., Makatsariya A.D., Khizroeva D.Kh., et al. Thrombophilia as a key link in the pathogenesis of pregnancy complications. Prakticheskaya meditsina, 2012, no. 5, pp. 22-29. (in Russ.).

48. Serov V.N. Poslerodovye neyroendokrinnye zabolevaniya [Postnatalneuroendocrinediseases]. Moscow, Meditsina Publ., 1978. 246 p.

49. Serov V.N., Prilepskaya V.N., Ovsyannikova T.V. Ginekologicheskaya endokrinologiya [Gynecological endocrinology]. Moscow, MEDpress-inform Publ., 2012, pp. 279-326.

50. Serov V.N., Kan N.I. Clinical pathogenetic variants of ovarian hormone deficiency in women with metabolic syndrome. Akusherstvo i ginekologiya, 2004, no. 5, pp. 29-34. (in Russ.).

51. Castro L.C., Avina R.L. Maternal obesity and pregnancy outcomes. Current Opinion in Obstetrics and Gynecology, 2002, vol. 14, no. 6, pp. 601-606. DOI:10.1097/00001703-200212000-00005.

52. Shaw G.M., Velie E.M., Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA: The Journal of the American Medical Association, 1996, vol. 275, no. 14, pp. 1127-1128.

53. Werler M.M., Louik C., Shapiro S., Mitchell A.A. Prepregnant weight in relation to risk of neural tube defects. JAMA: The Journal of the American Medical Association, 1996, vol. 275, no. 14, pp. 1089-1092.

54. Berikhanova R.R. Osobennosti techeniya beremennosti, rodov, poslerodovogo perioda u patsientok s metabolicheskim sindromom. Kand. med. nauk. diss. Avtoref. [Peculiarities of pregnancy, childbirth, postpartum period in patients with metabolic syndrome. Cand. med. sci. diss. Synopsis]. Volgograd, 2009.

55. Sarkisova A.V. Techenie beremennosti i rodov u zhenshchin s metabolicheskim sindromom. Kand. med. nauk. diss. Avtoref. [The course of pregnancy and childbirth in women with metabolic syndrome. Cand. med. sci. diss. Synopsis]. Moscow, 2004.

56. Sokolov E.I., Manukhin I.B., Mochalov A.A., Nevzorov O.B. Hemostatic disorders and their correction in women with metabolic syndrome. Lechashchiy vrach, 2011, no. 3, pp. 43-47. (in Russ.).

57. Nikolaeva-Ball D.R., Kan N.I. The state of adaptive mechanisms of women with metabolic syndrome and gestosis in the third term of pregnancy. Biomeditsinskiy zhurnal, 2012, vol. 13, pp. 803-818. Available at: http://www.medline.ru/public/art/tom13/art67.html. (in Russ.).

58. Kuz’mina-Krutetskaya S.R., Repina M.A. Metabolicheskiy sindrom u zhenshchin [The metabolic syndrome inwomen]. St. Petersburg, N-L Publ., 2011. 76 p.

59. Chernukha E.A., Chernukha G.E. Management of pregnancy and childbirth in women with obesity. Akusherstvo i ginekologiya, 1992, no. 1, pp. 68-73. (in Russ.).

60. Makarov I.O., Shilov E.M., Petunina N.A., Borovkova E.I., Shemanaeva T.V., Bayramova M.A. The course of pregnancy, labor, and postpartum in women with metabolic syndrome. Rossiyskiy vestnik akushera-ginekologa, 2012, vol. 12, no. 3, pp. 36-41. (in Russ.).

61. Burumkulova F.F., Petrukhin V.A., Kovalenko T.S., Titova T.V., Golovchenko M.A. Gestational diabetes – an interdisciplinary problem. Mat. X yubileyn.Vseross. nauch. foruma “Mat’ i Ditya” [Proc. 10^th Jubilee All-Russ. Sci. Forum “Mother and Child”]. Moscow, “MEDI Ekspo” Publ., 2009, pp. 30-31.

62. Gorokhova L.G. Dinamika obmena uglevodov i lipidov v sisteme mat’-plod-novorozhdennyy pri ozhirenii u zhenshchin. Kand. biol. nauk. diss. Avtoref. [Dynamics of carbohydrate and lipids exchange in the system mother-fetus-newborn in women with obesity. Cand. biol. sci. diss. Synopsis]. Irkutsk, 1995. 19 p.

63. Erchenko E.N. Patofiziologicheskie osobennosti uglevodnogo i lipidnogo obmenov i sostoyanie novorozhdennykh u beremennykh s izbytochnoy massoy tela i ozhireniem. Kand. med. nauk. diss. Avtoref. [Pathophysiological features of carbohydrate and lipid metabolism, and newborns status in pregnant women with overweight and obesity. Cand. med. sci. diss. Synopsis]. Moscow, 2009. 28 p.

64. Perederyaeva E.B. Osnovnye printsipy vedeniya beremennosti i bezopasnogo rodorazresheniya u zhenshchin s metabolicheskim sindromom. Kand. med. nauk. diss. Avtoref. [Basic principles of pregnancy management and safe delivery in women with metabolic syndrome. Cand. med. sci. diss. Synopsis]. Moscow, 2006. 24 p.

65. Perederyaeva E.B., Pshenichnikova T.B., Baymuradova S.M., Makatsariya A.D. Management of pregnancy and childbirth in patients with metabolic syndrome and thrombophilia. Vrach, 2006, no. 14, pp. 45-47. (in Russ.).